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Parkinson’s disease (PD) is a progressive neurodegenerative condition primarily involving the loss of dopaminergic neurons of 
the substantia nigra pars compacta (SNpc). This leads to a variety of symptoms and signs, including the primary motor deficits 
of tremor, bradykinesia, and rigidity, as well as other nonmotor problems such as cognitive, affective, and autonomic disturban-
ces that may have pathology outside of this dopaminergic pathway degeneration. Of all neurological diseases, PD has several fea-
tures that make it one of the most promising targets for clinical gene therapy. The internment of the major pathology to a compact 
localized neuronal population and the anatomy of the basal ganglia circuitry demonstrate that global gene transfer is not required, 
and there are well-defined sites for gene transfer. This review summarizes the studies of gene transfer using viral vectors and 
three separate gene transfer strategies currently being pursued for PD. 
 




Parkinson’s disease (PD) is one of the most-common 
neurodegenerative disorders, and is characterized by rigi-
dity, tremor, akinesia and gait disorder. The pathoanatomi-
cal basis for the predominant motor symptoms constitutes 
the loss of catecholaminergic neurons, especially dopa-
minergic neurons of the substantia nigra pars compacta 
(SNpc), in the adult brain at a pace far more rapid than 
that of normal aging.14) This cell death can take place over 
a period of 20 years or more, and the clinical symptoms 
of PD are not exhibited until a loss of -80% of striatal 
dopamine has occurred, representing a loss of -50% of 
the dopaminergic cell bodies within the SNpc.20)24) 
Traditional pharmacological treatments for PD focus 
on the direct replacement of dopamine by the administ-
ration of the dopamine precursor levodopa (L-dopa), or 
dopamine agonists, in combination with agents that act to 
prolong the action of dopamine at the synapse or prevent 
breakdown of dopamine. However, treatment with L-dopa 
becomes less efficacious over time and can lead to debi-
litating side effects such as dyskineasia, hallucinations and 
disorientation. Direct augmentation of dopamine does no-
thing to halt the progress of the disease, and addition of 
exogenous dopamine to compromised systems may cont-
ribute to the ongoing pathology.19) Thus, gene therapy 
strategies involving the transfer of gene encoding factors 
that increase dopaminergic cell phenotype and survival 
represent an innovative approach in attacking this disease.34) 
PD is particularly amenable to treatment using a gene 
therapy strategy for several reasons：1) the identification 
of an active and preventable cell death process occurring 
within the substantia nigra (SN)；2) the confinement of 
the initial pathology of the disease to discrete locations 
within the brain；3) the progression of the disease over 
a long time-frame；and 4) neurodegenerative diseases like 
PD are, by definition, chronic, so any treatment options 
must be long-lasting or permanent. This makes PD par-
ticularly suited to treatment with viral vectors, in which 
a single application of a vector can result in prolonged, 
stable transgene expression, with the production of phy-
siologically relevant levels of enzymes involved in the do-
pamine synthesis pathway, or prolonged growth factor 
production over several months to promote reinnervation 
of the damaged nigrostriatal pathway.34) 
Efficient vector systems for transduction of neurons 
have been developed, such as recombinant adeno-asso-
ciated (AAV) virus,41) adenovirus3) and lentivirus.33) This 
has been coupled with the optimization of manufacturing 
methods for these vectors to produce pure, high-titer vec-
tor stocks suitable for use in the human brain,5) thus 
enabling infusion of a small volume into brain tissue to 
transduce a maximal number of cells. However, there are 
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at least three separate gene transfer strategies currently 
being pursued in an effort to combat PD. This review 
provides a description of viral vectors and the progress 
of research on these various gene therapy strategies. 
 
Viral vectors for PD gene therapy 
Virus vectors can efficiently deliver genes to neurons 
and other neural cells in vitro and in vivo. These vectors 
allow us to monitor neurobilogical functions, replace, cor-
rect, express or block expression of target genes, tag cells 
for fate determination, and change the physiological state 
of specific cell populations. Gene transfer to the brain 
using viral vectors offers the advantage of being less 
invasive than transplantation techniques, leaving the stria-
tal circuitry undisturbed by cellular implants and elimi-
nating the risk of unwelcome host immune responses or 
tumor formation. 
 
Adeno-associated virus vectors 
Adeno-associated viruses (AAVs) are small, non-en-
veloped, single-stranded DNA viruses of the parvovirus 
family.41) The wild type AAV genome is 4.7kb and inte-
grates into the genome at a specific site on chromosome 
19. No human disease has been associated with AAV 
infection. There are at least seven serotypes known. Re-
cently, additional types were recovered from mammalian 
tissue samples and some are currently being analyzed for 
their potential use as vectors.21) Different serotypes infect 
tissues with varying efficiency. The serotype most com-
monly used for AAV vectors is serotype 2, which infects 
the brain and retina very well, and thus has been used for 
a wide spectrum of applications targeting these organs.4)11) 
AAV1 infects muscle well. As more and more AAV sero-
types are being characterized and different serotype capsids 
are combined to generate novel tropisms, there is the po-
tential that tissues that have not been easily infected with 
the current AAV serotypes may become amenable to AAV-
based gene transfer in the future. Recent work supports 
the use of other AAV serotypes in brain-directed gene 
transfer. The properties of AAV4 and AAV5 differ from 
those of AAV2；AAV5 diffuses more widely, and AAV4 
primarily transduces ependymal cells.12) In the cerebellum, 
AAV5 transduces purkinje cells, but not granule cells, with 
high efficiency.1) This is probably due to the selective 
expression of the AAV5 receptor on specific neuronal 
types (J. A. Chiorini, unpublished data). Other serotypes 
of AAV may also show distinct tropisms when injected 
into the brain. Although AAV vectors are highly effective 
for gene delivery and are non-toxic, they have a relatively 
small transgene capacity (4-5kb). This can be overcome 
by the infection of cells simultaneously with two AAV 
vectors, which can recombine to generate a larger ge-
nome.13) Studies in peripheral tissues show that transgenes 
are typically retained as extrachromosomal elements, but 
they can also integrate randomly into the genome.6) A 
number of clinical trials evaluating the use of AAV vectors 
for genetic and acquired diseases are currently underway. 
The brain is the target for monogenetic metabolic disor-
ders, such as canavan disease26) or degenerative disorders 
such as Parkinson’s disease.28) 
 
Adenovirus vectors 
Adenoviruses (Ad) are non-enveloped icosahedral DNA 
viruses with a 36-kb genome. With over 50 different 
human adenoviral serotypes, current vectors are primarily 
derived from those known as 2 and 5 - the most common 
serotypes to which most adults have been exposed.29) The 
deletion of essential genes, typically E1, renders the ade-
novirus replication deficient and makes room for the 
insertion of an expression cassette. Adenovirus-based vec-
tors have been most extensively evaluated in clinical stu-
dies. The advantages of utilizing adenovirus vectors for 
gene therapy include：1) they are easy to propagate in 
high titers；2) they can infect most cell types；and 3) they 
can be manipulated to accommodate large DNA inserts. 
First-generation Ad vectors have significant potential 
in therapies where only a limited duration of gene expres-
sion is necessary and permanent expression of the trans-
ferred gene, which may lead to undesired effects, is not 
required. The induction of angiogenesis is an application 
that meets these criteria. A vaccine vehicle is another 
application for adenovirus vectors, in which long-term 
expression is not desirable and the induction of immune 
responses is wanted.51) Various attempts have been made 
to change the immunogenicity of first-generation Ad vec-
tors by deleting more genes from their adenovirus genome 
by creating helper-dependant vectors (gutless or gutted 
vectors).32) Expression from gutless vectors has been ob-
served for up to 6 months without inflammation in vivo. 
However, there are no in vivo data, thus far from parkin-
sonian models.47) Efficient in vivo regulation of transgene 
expression has been shown with a Tet-off adenovirus sys-
tem.10) Transient rotational behavior has been induced after 
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D2 receptor；this might be applicable for parkinsonian 
syndromes with concurrent striatal degeneration.48) 
 
Lentivirus vectors 
Lentiviral (LV) vectors can infect dividing and non-
dividing cells, broadening their potential application to 
target cell types unable to be infected with retroviral vec-
tors.27) The vector integrates its DNA into the host genome 
at active gene loci, raising concerns of the possible trans-
activation of oncogenes or disruption of host genes.  
Studies in animals using gene transfer to hemaopoietic 
stem cells have shown the successful correction of genetic 
hematological disorders such as thalassemia, as well as 
successful gene transfer to the brain and liver.27) Persistent 
gene expression in vivo has been reported for at least 5-
13 months.45) The safety of LV transfection has been impro-
ved by further deletion of the HIV-1 envelop and virulence 
genes, the segregation of viral components on distinct 
plasmids and the development of self-inactivating vec-
tors.2) Recently, a self-inactivating Tet-on TH LV showed 
regulatory capability in vivo over two orders of magni-
tude in 6-OHDA-depleted striatum, however, no bioche-
mical or behavioral consequences were examined.49) 
 
Strategies for gene therapy in PD 
Three separate gene therapy strategies that may be used 
to attack this disease (Fig. 1) exist. First, the transfer of 
genes involved in dopamine biosynthesis may relieve the 
immediate motor symptoms of the disease through sus-
tained local production of dopamine in a manner similar 
to systemic administration of oral L-dopa (dopamine rep-
lacement therapy). Second, transfer of growth factor genes 
such as glial-cell-line-derived neurotrophic factor (GDNF) 
might prevent further dopaminergic cell death (neurotro-
phic factor therapy). Third, the transfer of genes invol-
ved in inhibitory neurotransmission could be used to 
reduce the activity of brain nuclei that become overactive 
in PD (GAD gene therapy).34) 
 
Dopamine replacement therapy 
The rate-limiting enzyme in dopamine (DA) production 
is tyrosine hydroxylase (TH), which converts the amino 
acid tyrosine to L-dopa (Fig. 2). L-dopa is then metabo-
lized to dopamine by aromatic amino acid decarboxylase 
(AADC).43) Another factor influencing this pathway is 
the essential TH cofactor 6-tetrahydrobiopterin (BH4), the 
level of which is limited by availability of the enzyme 
GTP-cyclohydrolase I (GCH1).42) In a 2000 study, TH 
expression in the striatum of 6-OHDA lesioned rats was 
achieved by AdV- or HSV-mediated transduction.36) 
This decreased apomorphine-induced rotation by 30-65% 
but was not corroborated in later studies with adenoviral 
gene transfer.10) HSV-TH transfer also led to higher po-















Fig. 1. Gene therapy strategies for PD. The putative event and 
functional consequences involved in cell loss of DA neurons and
depicted. There are three separate gene therapy strategies,
which are dopamine replacement therapy, neurotrophic factor
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Fig. 2. The dopamine synthesis and storage pathway. Tyrosine is
converted to L-dopa by the enzyme tyrosine hydroxylase (TH), a
reaction that also requires the TH cofactor 6-tetrahydrobioptein
(BH4). Guanosine triphosphate cyclohydrolase I (GCH1) is the
first and rate-limiting enzyme involved in BH4 synthesis. Conversion
of L-dopa to dopamine requires the enzyme aromatic amino






J of The Kor Soc of Ster and Func Neurosur 2005;1:25-30 
 
 28 
to abate after 2 weeks in Ad-treated rats but were preser-
ved after delivery of the herpes simplex virus (HSV) for 
up to 16 months, despite TH immunoreactivity in only 
5-300 striatal cells.16) Thus, the functional connection 
between TH transfer and rotational improvement in the 
latter study was cast in doubt.39) The AAV-mediated de-
livery of AADC to the striatum after stable 6-OHDA le-
sions, allowed for L-Dopa-regulated dopamine increases, 
as measured by striatal microdialysis. Expression was stable 
for 6-12 months.35) 
Various vector systems have been used in recent prec-
linical studies to deliver different combinations of these 
enzymes. These studies include multicistronic LV simul-
taneously encoding GCH1, TH and AADC,2) combinations 
of AAV vectors separately encoding GCH1 and TH30) or 
GCH1, TH and AADC40)；and HSV vectors coexpressing 
AADC and TH.46) In all cases, the coexpression of enzy-
mes and functional recovery of the experimentally lesioned 
animals was observed. 
 
Neurotrophic factor therapy 
Various neurotrophic factors with putative effects on 
the nigrostriatal dopamine system have been evaluated for 
their therapeutic potential in PD. The most potent trophic 
factor for midbrain dopaminergic neurons is GDNF, which 
is a homodimeric member of the transforming growth 
factor beta (TGF-β) superfamily.37) The GDNF receptor 
components GDNFR-α/GFR-α and c-Ret are both expre-
ssed in adult SN but not, or only weakly, in the striatum.23) 
GDNF may mediate at least three different effects9)31)：
1) an increase in striatal dopamine synthesis and release 
in normal and lesioned individuals, partly mediated by 
transcriptional effects；2) protection of dopaminergic 
neuronal cell bodies against some (but not all) toxic 
insults；and 3) local sprouting and outgrowth of dopa-
minergic fibres with possible reinnervation of target regions. 
These effects may dissociate from each other depending 
on the dose, site of application and time-point after 
injury.17) 
A 1998 study regarding adenoviral-mediated transfer 
of GDNF showed protection from 6-OHDA-induced cell 
death following infusion of the vector adjacent to the cell 
bodies of the SN7) and into the striatum.8) A direct com-
parison between the benefits of infusing GDNF-encoding 
vectors into either the SN or striatum resulted in greater 
prevention of behavioral deficits and greater preservation 
of striatal innervation. A potential problem with the use 
of adenoviral vectors is the production of an inflamma-
tory response and the consequent downregulation of tran-
gene levels following injection into the brain over time. 
Other groups have reported the use of AAV- or LV-me-
diated delivery of GDNF to ensure long-term transgene 
expression and have demonstrated both the neuroprotec-
tion22) and restoration of function and innervation in the 
rat model of PD, with transgenic GDNF still at maximal 
levels six months after gene transfer.50) 
 
GAD gene therapy 
In the current model of basal ganglia dysfunction in 
Parkinson’s disease, nigrostriatal degeneration renders the 
subthalamic nucleus overactive with ensuing hyperacti-
vity in the SN pars reticulata (SNr) and internal globus 
pallidus (Gpi). This, in turn, dampens motor output struc-
tures. Deep brain stimulation in the subthalamic nucleus 
(STN) curbing excitatory outflow from the STN is the 
most successful in treating end-stage complications related 
to Parkinson’s disease therapy. A similar down-regulation 
of non-physiological hyperactivity of the STN might be 
achieved pharmacologically by enhancing the level of the 
inhibitory neurotransmitter GABA, which is synthesized 
by GAD. This hypothesis has been tested by the overex-
pression of AAV-GAD65/67 in the STN of rats later le-
sioned with 6-OHDA in the MFB.38) Ad-GAD67-mediated 
transduction of cultured glial cells or LV transfer of GAD65/ 
GAD67 in cultured astrocytes has previously been proven 
to enhance GABA release.18)44) Expression in vivo is stable 
for 4-5 months.38) Whereas baseline GABA levels of the 
STN are unchanged, local GABA release following the 
electrical stimulation of the STN is increased four-fold 
and a shift in the majority of target neurons in the SNr 
from an excitatory to an inhibitory phenotype is elicited.38) 
AAV-GAD65 is much more effective than AAV-GAD67；
this appears to be related to lower expression levels of 
AAV-GAD67. AAV-GAD65-treated animals exhibit less 
apomorphine-induced rotation and less behavioral side 
bias (head position bias, forelimb use). Even more im-
portant, 35% of dopaminergic cells in the SNpc survive 
following the 6-OHDA lesion in GAD65-expressing ani-
mals (as opposed to 1%).38) Neuroprotection by GAD65/ 
67 transfer has also been observed in chronically lesioned, 
aged rats.15) Combining neuroprotection with functional 
compensation is attractive；a Phase I clinical trial has been 












PD is a debilitating, neurodegenerative disorder arising 
from the loss of dopaminergic neurons in the SNpc and 
subsequent depletion of striatal DA levels, resulting in 
distressing motor symptoms. Current mainstay treatments 
for PD, such as administration of L-dopa, treat the motor 
symptoms but do little to alter the ongoing pathology. 
Accordingly, alternative long-term treatment strategies such 
as gene therapy are being pursued. The replacement of 
missing or defective genes may be considered in the rare 
cases of hereditary PD with loss-of-function mutations. 
Viral vector systems capable of efficiently transducing 
neurons, such as AAV, have been developed, along with 
protocols for the manufacture of pure vector stocks sui-
table for application to the human brain. A clinical trial, 
based on GAD gene transfer to the subthalamic nucleus 
using an AAV vector, is poised to recruit patients soon.15) 
The trial is a dose-escalation safety study in which three 
cohorts of patients will receive between 1011 and 1012 
particles of rAAV-GAD at the time of STN stimulator 
implantation25) as approved by the US Food and Drug 
Administration. 
Newer approaches include attempts to influence detri-
mental cell signaling pathways and to restrain overactive 
basal ganglia structures. Nevertheless, current models of 
PD do not address issues regarding long-term protein ex-
pression；the choice of target structures, transgenes and 
safety remain to be solved. 
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